glp 1 uses GLP-1 Agonists - What is it? The GLP-1 revolution: What UAB
Description
The industry is anticipated to expand at a CAGR of 13.7% from 2025 to 2035
We think this is a big deal. The company plans to seek regulatory approval for orforglipron for weight management by the end of this year and for the treatment of type 2 diabetes in 2026
Duration of effect this is a key question that has not yet been studied in retrospective or prospective trials on addiction
It also raises questions about the best way to move to a maintenance dose once desired weight loss is achieved
